Ibuprofen Decreases Spontaneous Activity and Enhances Nerve-Evoked Contractions to Minimize Mitomycin C-Induced Bladder Dysfunction

Inflammation may play a causal role in urological side effects reported following intravesical mitomycin C (MMC). Our aim was to investigate the effects of the nonsteroidal anti-inflammatory drug ibuprofen (IBU) on the cytotoxic potency of MMC and the potential for IBU to protect against bladder dysfunction. Malignant (RT4, T24) and normal (UROtsa) urothelial lines were treated with MMC followed by ibuprofen, with cell viability and caspase-3 activity assessed. Female C57BL/6JArc mice (Saline/Control, MMC, Saline + IBU, and MMC + IBU) received intravesical treatment (1 hour) with saline or MMC (2 mg/ml), with IBU (1 mg/ml) delivered in drinking water (for 7 days). Voiding pattern analysis was conducted prior to and following (1, 3, 7 days) treatment. A whole-bladder preparation was used to assess compliance, contractile responses, and urothelial-mediator release. Ibuprofen selectively increased the cytotoxic potency of MMC and caspase-3 activity in both malignant cells lines but not in UROtsa. MMC significantly increased voiding frequency at 24 hours and 3 days, whereas administration of ibuprofen significantly reduced this effect. MMC significantly increased the frequency of spontaneous contractions from 2.3 ± 0.5 contractions/min in saline controls to 4.8 ± 0.16 contractions/min, with ibuprofen protecting against this change. Interestingly, although nerve-evoked responses were not altered by MMC, they were increased in both IBU groups. Ibuprofen improved voiding dysfunction following MMC treatment by reducing spontaneous phasic activity and enhancing nerve-mediated contractions. Ibuprofen use in bladder cancer patients may help to minimize the urological adverse effects associated with intravesical MMC.

[1]  D. Newling,et al.  Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. , 2018, European urology.

[2]  D. Tousoulis,et al.  The Role of Inflammation , 2018 .

[3]  T. Daabees,et al.  Effect of Some Prostanoids Modulators and Cyclooxygenase Inhibitors on Rat Bladder Detrusor Muscle in Normal and Cyclophosphamide- Induced Cystitis , 2017 .

[4]  David C. Miller,et al.  A Management Algorithm for Mitomycin C Induced Cystitis , 2017, Bladder cancer.

[5]  R. Chess-Williams,et al.  Gemcitabine: Selective cytotoxicity, induction of inflammation and effects on urothelial function , 2017, Toxicology and applied pharmacology.

[6]  R. Chess-Williams,et al.  Enhanced urothelial ATP release and contraction following intravesical treatment with the cytotoxic drug, doxorubicin , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  R. Chess-Williams,et al.  Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  T. Christmas,et al.  Destruction of the bladder by single dose Mitomycin C for low‐stage transitional cell carcinoma (TCC) – avoidance, recognition, management and consent , 2014, BJU international.

[9]  Christopher P. Filson,et al.  Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. , 2014, Urologic oncology.

[10]  T. Gevaert,et al.  Chronic administration of anticholinergics in rats induces a shift from muscarinic to purinergic transmission in the bladder wall. , 2013, European urology.

[11]  C. Kistler,et al.  Diagnosis of urinary incontinence. , 2013, American family physician.

[12]  A. Kibel,et al.  Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment. , 2013, The Journal of urology.

[13]  R. Chess-Williams,et al.  Induction of inflammatory cytokines and alteration of urothelial ATP, acetylcholine and prostaglandin E2 release by doxorubicin. , 2013, European journal of pharmacology.

[14]  Joanne M. Smith,et al.  Health Evaluation of Experimental Laboratory Mice , 2012, Current protocols in mouse biology.

[15]  T. Wilt,et al.  Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic review , 2012, BJU international.

[16]  S. Kobayter,et al.  Prostaglandin E2 induces spontaneous rhythmic activity in mouse urinary bladder independently of efferent nerves , 2012, British journal of pharmacology.

[17]  C. Franco,et al.  Histological changes due to intravesical instillation of mitomycin C. , 2012, Archivos espanoles de urologia.

[18]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[19]  R. Vennekens,et al.  Functional characterization of a chronic cyclophosphamide‐induced overactive bladder model in mice , 2011, Neurourology and urodynamics.

[20]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[21]  Garret A. FitzGerald,et al.  Prostaglandins and Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[22]  A. Tewari,et al.  Role of inflammation in bladder function and interstitial cystitis , 2011, Therapeutic advances in urology.

[23]  S. Landas,et al.  Instillation of mitomycin C after transurethral resection of bladder cancer impairs wound healing: an animal model. , 2008, Anticancer research.

[24]  J. Roppolo,et al.  Spontaneous contractions evoke afferent nerve firing in mouse bladders with detrusor overactivity. , 2009, The Journal of urology.

[25]  A. Miner,et al.  Potential for control of detrusor smooth muscle spontaneous rhythmic contraction by cyclooxygenase products released by interstitial cells of Cajal , 2009, Journal of cellular and molecular medicine.

[26]  D. Lamm,et al.  Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. , 2008 .

[27]  Zhe Wang,et al.  Regulation of smooth muscle contractility by the epithelium in rat vas deferens: role of ATP‐induced release of PGE2 , 2008, The Journal of physiology.

[28]  R. Chess-Williams,et al.  67 ENDOGENOUSLY RELEASED ACH ALTERS BLADDER SENSATION IN A MECHANISM INVOLVING BOTH NICOTINIC AND MUSCARINC RECEPTORS , 2007 .

[29]  A. Brading,et al.  The Use of the Isolated Mouse Whole Bladder for Investigating Bladder Overactivity , 2006, Journal of Pharmacology and Experimental Therapeutics.

[30]  T. Becopoulos,et al.  Histological changes of the bladder mucosa following the administration of BCG, Adriamycin and RO 10-9359 , 2006, International Urology and Nephrology.

[31]  D. Coomans,et al.  Mitomycin C and epirubicin: functional bladder damage in rats after repeat intravesical instillations. , 2005, The Journal of urology.

[32]  Fatima S. Khwaja,et al.  Ibuprofen Inhibits Survival of Bladder Cancer Cells by Induced Expression of the p75NTR Tumor Suppressor Protein , 2004, Cancer Research.

[33]  D. Djakiew,et al.  Molecular characterization of the loss of p75NTR expression in human prostate tumor cells , 2001, Molecular carcinogenesis.

[34]  G. Sgaragli,et al.  Mechanical response to electrical field stimulation of rat, guinea-pig, monkey and human detrusor muscle: a comparative study , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[35]  F. Stewart,et al.  Bladder damage in mice after single and repeated intravesical instillations of mitomycin C or doxorubicin. , 1993, The Journal of urology.

[36]  C. Ed,et al.  Complications of intravesical chemotherapy. , 1992, The Urologic clinics of North America.

[37]  E. Crawford,et al.  Complications of intravesical chemotherapy. , 1992, The Urologic clinics of North America.

[38]  P. Lackner,et al.  Modulation of equine tracheal smooth muscle contractility by epithelial-derived and cyclooxygenase metabolites. , 1991, Respiration physiology.

[39]  B. Coolsaet Bladder compliance and detrusor activity during the collection phase , 1985 .

[40]  B. Hirt [Anticancer research]. , 1981, Revue medicale de la Suisse romande.